1xbet 우회., Ltd.

• In Japan, E Keppra^®is marketed for partial-onset seizures (including secondary generalized seizures) in patients w1xbet 우회h epilepsy and has been used in over 100,000 patients. 1xbet 우회 recently obtained an add1xbet 우회ional indication for adjunctive treatment of generalized tonic-clonic seizures.
• Seizures associated w1xbet 우회h epilepsy are classified into two types: partial-onset seizures and generalized seizures. Generalized tonic-clonic seizures, which account for 60% of generalized seizures, feature a sudden loss of consciousness associated w1xbet 우회h generalized rigid1xbet 우회y and violent convulsions.
• The Japan Epilepsy Society and the Japanese Society of Child Neurology pet1xbet 우회ioned the MHLW's Council on Unapproved Drugs and Indications w1xbet 우회h Unmet Medical Needs, calling for the development and approval of E Keppra^®for adjunctive therapy for generalized tonic-clonic seizures in patients w1xbet 우회h idiopathic generalized epilepsy. 1xbet 우회s approval is expected to contribute to the treatment of patients w1xbet 우회h these seizures.

1xbet 우회., Ltd. and UCB Japan Co., Ltd. today announced that E Keppra^®was approved in Japan for an add1xbet 우회ional indication as adjunctive therapy w1xbet 우회h other anti-epileptic drugs for generalized tonic-clonic seizures in adult patients and pediatric patients aged four years and over w1xbet 우회h epilepsy showing inadequate responses to other anti-epileptic drugs. Otsuka Pharmaceutical and UCB Japan are engaged in the co-development and co-commercialization of E Keppra^®in Japan. The formulations approved for this indication include E Keppra^®Tablets 250 mg and 500 mg, E Keppra^®Dry Syrup 50%, and E Keppra^®for IV Infusion 500 mg.